KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Healthcare

GC Biopharma to launch first-in-class rare disorder medications in the global market

 17 total views,  1 views today

megha besuccess by megha besuccess
PUBLISHED: March 2, 2023 UPDATED: March 2, 2023
in Healthcare
0
GC Biopharma to launch first-in-class rare disorder medications in the global market

South Korea-based biopharmaceutical company, GC Biopharma Corporation plans to launch its first-in-class medications for rare disorders. The new drug will be available to patients across all the global markets.

The South Korean drug industry has become highly competitive over the years. Advancements happen at a fast pace in pharma all with the assistance of government funds and upliftments from time to time. There are several leading pharma companies, including GC Biopharma that hold a monopoly in the healthcare and pharma space. Although sizably smaller than the western counterparts such as Europe and the US, innovations are on a rise across the South Korean pharma sector which was valued at 25.4 trillion South Korean won in 2021.

With innovation, GC Biopharma desires to go a step forward. The corporation has signed a purchase agreement with Catalyst Biosciences, a US-based research and clinical development biopharmaceutical company. Via this agreement GC Biopharma has gained the orphan haematology disorder treatment candidates of Catalyst Biosciences.

Among a total of 3 candidates, only one has been disclosed so far. One of them is a treatment candidate for Marzeptacog alfa also known as MarzAA, a rare bleeding disorder. According to GC Biopharma, the treatment candidate has already gone through phase 3 global clinical trials. Till now, they have received quite a positive response in clinical trials. 

GC Biopharma is one of the leading players in South Korea’s healthcare sector. As per the company head, Huh Eun-Chul, they are confident that the new drug will make orphan disorders like MarzAA more administrable and manageable. 

There have been no detailed revaluations but GC Biopharma plans to disclose them at the right time. However, they do call out their goal to enhance the treatments for patients suffering from different orphan disorders. 

The purchase agreement has turned out well for Catalyst Biosciences. They have started to see a 55 percent rise in pre-market trading due to their fresh assets sale to GC Biopharma group. 

The bleeding disorder treatment market has grown in the last few decades. It is expected that the market will multiply by 7.8 percent from 2022 to 2030. The current $14 million worth of treatment and cure market can reach a rough estimation of 26 million in the next 7 years. South Korea is anticipated to become a major pharma partner by the same interval in the Asia-Pacific region.  

GC Biopharma is focusing on improving customer experience as well as expanding to an international customer base. With the agreement announcements, the company CEO Eun-Chul also shed light on their GreenGene F and Green Mono drugs used for treating haemophilia type A, a commonly found rare bleeding disorder. The Korean health authorities have approved both drugs. A good chunk of success in the control and prevention of bleeding episodes in patients has been visible through their intake.

Lately, GC Biopharma Corp. is indulging in more advancements in public health. The newly established Fil-finish Plant along with the BARYCELA varicella vaccine received pre-qualification from World Health Organization (WHO). GC Biopharma is devoted to enhancing the quality of healthcare solutions and aspires to continue to do so. 

 

 

What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: COVID-19healthcareinnovationR&D

Related Posts

INTIN introduces new digital healthcare products to improve quality of life
Healthcare

INTIN introduces new digital healthcare products to improve quality of life

November 27, 2021
Intin, a digital healthcare startup, honored with the ‘CES Innovation Award’ for technological prowess in healthcare
Healthcare

Intin, a digital healthcare startup, honored with the ‘CES Innovation Award’ for technological prowess in healthcare

November 20, 2021
Hyundai Mobis presented M.Brain, the world’s first in-vehicle brainwave measuring healthcare technology, reducing drowsiness-caused vehicular accidents.
Healthcare

Hyundai Mobis Unveils World’s 1st In-Vehicle Brainwave Tech M.Brain

July 24, 2021
SK’s drug-making unit SK Biopharmaceuticals revealed its target to become one of the world’s market-leading healthcare technology developers and providers.
Healthcare

SK’s Drug Maker Unit to Become a Globally Leading Healthcare Firm

July 6, 2021
AI-based medical tech startup VUNO partnered with Samsung to integrate the VUNO Med-Chest X-ray diagnostic solution with Samsung’s GM85 X-ray system.
AI

AI Medical Tech Startup VUNO Enhances Samsung’s X-ray System

July 2, 2021
Human-computer interaction tech startup Impressivo would offer its advanced sensing technologies to overseas companies, enhancing fitness and healthcare.
Healthcare

HCI Tech Startup Impressivo to Unite Fitness and Healthcare Solutions

July 2, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • Robots to help Police Patrol in South Korea

    0 shares
    Share 0 Tweet 0
  • South Korea plans Urban Air Mobility Air Taxi services by 2025

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • SK On to introduce South Korea’s first LFP Battery Prototype

    0 shares
    Share 0 Tweet 0
  • Outsourcing by Samsung to China Feared by Phone Parts Suppliers

    0 shares
    Share 0 Tweet 0
  • South Korea to commercialize Quantum Cryptography Communications

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • Netmarble subsidiary Metaverse Entertainment’s K-Pop virtual girl band MAVE has a smashing online debut

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |